920547 No Chemical pharma, Crystal Sea Fundamental Research and Analysis Report.
(920547) The current price of Chemical pharma Crystal Sea is 19.36 yuan, the medium and long-term price trend (weekly K-line MA10) is more, the current structure of weekly K-line is volatile, the recent price trend (daily K-line MA10) is more, and the current form of daily K-line is rising. The medium- to long-term price trend of the Shanghai Composite Index (weekly MA10) is bullish. Strong operations, mid-range valuation. Core indicators deducted non-ROE current 5.07, 107.48 YoY. Core metrics Operating cash flow/net profit 0.60 for the period, up -19.06 YoY. Core indicator price-to-earnings ratio PE current 22.46, up -45.92 YoY, 4.54 month-on-month. The core indicator price-to-book ratio PB was 2.04 in the current period, up -35.14 YoY and 4.54 YoY. Key indicator: Manufacturing PMI new orders stood at 50.60 this period, placing it at the 50th percentile over the past 10 years, up 2.22% year-on-year and 4.33% month-on-month.
Full report and figures: download the original Chinese file.
(920547) The current price of Chemical pharma Crystal Sea is 19.36 yuan, the medium and long-term price trend (weekly K-line MA10) is more, the current structure of weekly K-line is volatile, the recent price trend (daily K-line MA10) is more, and the current form of daily K-line is rising. The medium- to long-term price trend of the Shanghai Composite Index (weekly MA10) is bullish. Strong operations, mid-range valuation. Core indicators deducted non-ROE current 5.07, 107.48 YoY. Core metrics Operating cash flow/net profit 0.60 for the period, up -19.06 YoY. Core indicator price-to-earnings ratio PE current 22.46, up -45.92 YoY, 4.54 month-on-month. The core indicator price-to-book ratio PB was 2.04 in the current period, up -35.14 YoY and 4.54 YoY. Key indicator: Manufacturing PMI new orders stood at 50.60 this period, placing it at the 50th percentile over the past 10 years, up 2.22% year-on-year and 4.33% month-on-month.
Same variety and related reports
- 600267 Haizheng Pharmaceutical Fundamental Research and Analysis Report.
- Chemical pharma Chemical pharma Pharma & biotech Fuxiang shares 300497 fundamental data research analysis report.
- Healthcare services, Pharma & biotech, Huada Gene 300676 Fundamental Data Research and Analysis Report.
- Biologics, Pharma & biotech, 100g bio -688276 fundamental data research and analysis report.